Skip to main content
. 2024 Oct 29;14(10):e089375. doi: 10.1136/bmjopen-2024-089375

Table 3. Prevalence ratios of CIN in those 50+ vs 30–49 years of age.

Crude prevalence ratio (95% CI) Adjusted* prevalence ratio (95% CI)
Women with HIV
Any hrHPV
 CIN2+ 1.1 (0.80 to 1.6) 1.1 (0.80 to 1.6)
 CIN3+ 1.1 (0.70 to 1.6) 1.1 (0.70 to 1.6)
Women without HIV
Any hrHPV
 CIN2+ 0.78 (0.45 to 1.4) 0.78 (0.45 to 1.4)
 CIN3+ 0.81 (0.40 to 1.7) 0.81 (0.40 to 1.7)
*

Adjusted for history of cervical cancer screening.

CINcervical intraepithelial neoplasiaHPVhuman papillomavirus